Vergara Dangond, CristinaRichi Alberti, PatriciaCobo Ibáñez, María TatianaValverde Garrido, RicardoGarcía Yubero, CristinaTrives Folguera, LauraParedes Romero, María BeatrizEsteban Vázquez, AnaRomero Bogado, LizCámara Fernández, Isabel de laSteiner, MartinaPrats, IolandaMuñoz Fernández, SantiagoEt. al.2026-02-182026-02-182025Vergara-Dangond, C., Cobo-Ibáñez, T., Cueva-Nájera, G., Valverde-Garrido, R., García-Yubero, C., Trives-Folguera, L., Paredes-Romero, B., Esteban-Vázquez, A. V., Romero-Bogado, L., De La Cámara-Fernández, I., Steiner, M., Richi-Alberti, P., Acosta-Alfaro, A. V., Prats, I., & Muñoz-Fernández, S. (2025). Prevalence of psoriatic arthritis in patients with moderate-to-severe psoriasis in the era of biologics and small molecule therapies. Journal of Clinical Medicine, 14(23), 8359. https://doi.org/10.3390/jcm142383592077-0383https://hdl.handle.net/11268/16834This study aims to estimate the prevalence of psoriatic arthritis (PsA) and associated factors in patients with moderate-to-severe psoriasis. The study develops a retrospective, single-center study of a cohort of psoriasis patients in standard follow-up in a dermatology department from July 2008 to January 2024. Patients ≥18 years with moderate-to-severe psoriasis were included and classified into three groups according to the treatment received: group 1, biologics or small molecules with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs); group 2, only csDMARDS; and group 3, non-pharmacological treatments. Demographic and clinical variables were collected.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/PrevalenciaPsoriasisArtritis psoriáticajournal article10.3390/jcm14238359open accessInvestigación médicaMedicina preventivaLucha contra las enfermedadesGoal 3: Ensure healthy lives and promote well-being for all at all ages